Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Neratinib + Pictilisib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Neratinib||Nerlynx||HKI-272|PB272||HER2 Inhibitor 26||Nerlynx (neratinib) inhibits the ERBB2 (HER2) receptor as well as EGFR, resulting in decreased proliferation of HER2 and EGFR expressing tumor cells (PMID: 15173008). Nerlynx (neratinib) is FDA approved for use in patients with early stage ERBB2 (HER2)-positive breast cancer following Herceptin (trastuzumab)-based therapy, and in combination with Xeloda (capecitabine) in patients with advanced/metastatic ERBB2 (HER2)-positive breast cancer who have received two or more anti-ERBB2 (HER2) regimens (FDA.gov).|
|Pictilisib||GDC-0941|GDC0941|GDC 0941||PI3K Inhibitor (Pan) 38||Pictilisib (GDC-0941) inhibits isoforms of PI3K, which inhibits PI3K/AKT signaling resulting in antitumor activity, including inhibition of tumor growth (PMID: 19584227).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 L755S||breast cancer||sensitive||Neratinib + Pictilisib||Preclinical - Cell culture||Actionable||In a preclinical study, Nerlynx (neratinib) and Pictilisib (GDC-0941) synergistically inhibited viability of transformed breast epithelial cells expressing ERBB2 L755S in culture (PMID: 31135266).||31135266|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|